

# Liora Schultz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2161222/publications.pdf>

Version: 2024-02-01

13  
papers

589  
citations

1307594

7  
h-index

1281871

11  
g-index

14  
all docs

14  
docs citations

14  
times ranked

814  
citing authors

#	ARTICLE	IF	CITATIONS
1	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	30.7	273
2	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	1.6	79
3	Driving CAR T cell translation forward. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	61
4	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	1.4	51
5	Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. <i>PLoS ONE</i> , 2019, 14, e0219547.	2.5	38
6	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. <i>Blood Advances</i> , 2022, 6, 600-610.	5.2	32
7	Mechanisms of and approaches to overcoming resistance to immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 226-232.	2.5	23
8	Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 1985.	4.8	7
9	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
10	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. <i>Neuro-Oncology</i> , 2021, 23, i49-i50.	1.2	6
11	CD81 costimulation skews CAR transduction toward naive T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	6
12	Summary of COVID-19 clinical practice adjustments across select institutions. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28411.	1.5	4
13	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2